Faculty will provide current perspectives on the diagnosis, pathogenesis, and care of patients with myasthenia gravis, ocular and MuSK myasthenia. Case presentations demonstrate a practical approach to identification, evaluation, and management of common and more challenging patients in the clinical setting.
This program complements C19: Neuromuscular Junction Disorders II: Toxins, Lambert-Eaton Syndrome, and Less Common Disorders of Neuromuscular Transmission, but covers independent topics.
Participants should be familiar with the diagnosis and management of patients with myasthenia gravis and related disorders; learn to critically select therapies; and be able to distinguish myasthenia gravis, MuSK myasthenia, Lambert-Eaton syndrome, and recognize the less common disorders of neuromuscular transmission.
Medical Knowledge, Patient Care
Program Speakers - Tentative
10:30 AM - 10:35 AM
Laura Marie Tormoehlen MD
10:35 AM - 11:25 AM
What's in the Diagnosis: Seropositive, MuSK, and Seronegative Myasthenia Gravis
Janice M. Massey MD, FAAN
11:25 AM - 12:15 PM
Treatment of Autoimmune Myasthenia Gravis: Evidence-based and New Developments
Jeff Guptill MD
12:15 PM - 12:30 PM
Questions and Answers
Jeff Guptill, MD
Dr. Guptill has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Argen-X, Becton Dickinson, and Grifols. Dr. Guptill has received research support from Grifols Foundation, and Bioverativ.
Janice M. Massey, MD, FAAN
Dr. Massey has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Revance and Quatrobio.
Laura Marie Tormoehlen, MD
Dr. Tormoehlen has nothing to disclose.
Ready to register for the 2018 AAN Annual Meeting?